Why Add Genetic Testing to Your AMD Workflow
Risk Stratification
Personalized risk stratification based on 14 genetic markers across 12 genes (including CFH, ARMS2, C3). Defined time windows for 2-, 5-, and 10-year progression.
Supplement Guidance
For approximately 15% of patients, certain genetic profiles indicate 3x risk from zinc-based AREDS supplements (≥25 mg/day). US Patent-protected discovery.
Monitoring Schedule
Risk-adjusted follow-up recommendations. Higher-risk patients get tighter monitoring intervals — improving early detection of conversion to wet AMD.
Patient Engagement
Plain-language patient reports increase understanding and compliance. Patients who understand their risk are more likely to adhere to follow-up schedules.
Seamless Integration Into Your Practice
Order the Kit
Order online or through your practice account. Kits ship directly to your office or to the patient.
Collect the Sample
Simple buccal swab collected chairside in under a minute. No venipuncture required.
Receive the Report
Clinician and patient reports delivered within 6–8 weeks. Personalized risk profiles with supplement guidance.
Counsel the Patient
Use the structured clinician report to guide supplement selection, monitoring schedule, and patient education.
What Your Report Includes
The clinician report is designed for rapid interpretation. Each section maps to a specific clinical decision point.
Genetic Risk Score
Composite score from 14 genetic markers across 12 genes (CFH, ARMS2, C3, and more) with population percentile comparison.
Risk Category
Personalized risk stratification with 2-, 5-, and 10-year progression estimates.
Supplement Recommendation
Zinc-containing vs zinc-free AREDS2 recommendation based on CFH genotype analysis.
Evidence Summary
Key citations supporting each recommendation, linked to peer-reviewed literature for full transparency.